InnoCare reports positive Phase III topline results for soficitinib (ICP-332), with the oral TYK2 inhibitor meeting the primary endpoint in moderate-to-severe atopic dermatitis.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
InnoCare Pharma Announces Positive Phase III Results for Soficitinib in Atopic Dermatitis InnoCare Pharma reported that its registrational Phase III trial of oral soficitinib (ICP‑332), a selective TYK2 inhibitor, met the primary endpoint in patients with moderate‑to‑severe atopic dermatitis, achieving statistically significant and clinically meaningful improvement versus placebo.
Multiple secondary endpoints were also met, supporting a consistent treatment effect. Detailed efficacy and safety data will be presented at upcoming international scientific congresses and submitted for peer‑review publication.
Registrational Phase III Trial Design
The Phase III study (NCT06775860) was a randomized, double-blind, placebo-controlled, multicenter registrational clinical trial designed to evaluate the efficacy, safety, and tolerability of oral soficitinib in patients with moderate-to-severe atopic dermatitis.
According to InnoCare, the trial successfully met its primary endpoint with statistical significance and clinically meaningful improvement over placebo. In addition, multiple secondary endpoints were achieved, demonstrating a consistent treatment effect across efficacy measures.
The company has not yet released detailed numerical efficacy results, and additional clinical findings are expected to be presented in future scientific publications and congress presentations.
Safety Profile Remained Consistent with Earlier Studies
InnoCare reported that soficitinib demonstrated a good safety profile that was consistent with previous clinical studies. No new safety signals were identified during the Phase III trial.
The company noted that comprehensive safety analyses, together with detailed efficacy outcomes, will be shared following presentation at international scientific meetings and publication in peer-reviewed journals.
Soficitinib Targets TYK2-Mediated Inflammatory Signaling
Soficitinib (ICP-332) is a potent and selective oral TYK2 inhibitor being developed for the treatment of T-cell-related autoimmune disorders. TYK2 plays a critical role in the JAK-STAT signaling pathway, which regulates immune and inflammatory responses involved in several chronic inflammatory diseases.
Beyond atopic dermatitis, InnoCare is advancing the development of soficitinib across multiple dermatologic and autoimmune indications, including vitiligo, psoriasis, nodular prurigo, and chronic spontaneous urticaria.
Company Plans Regulatory Filing Following Phase III Program
Commenting on the topline results, Dr. Jasmine Cui, Co-founder, Chairwoman, and Chief Executive Officer of InnoCare Pharma, said the company is encouraged by the positive Phase III findings in patients with moderate-to-severe atopic dermatitis.
She noted that InnoCare plans to complete the Phase III development program and advance regulatory submissions with the goal of making soficitinib available as a new treatment option for patients with atopic dermatitis and other autoimmune diseases.
Atopic Dermatitis Continues to Pose a Significant Global Health Burden
Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense itching, eczema, and substantial impairment in quality of life. According to the World Health Organization’s Global Burden of Disease study, approximately 230 million people worldwide are affected by atopic dermatitis, making it one of the leading non-fatal diseases globally.
In China, nearly 70 million people are estimated to be living with atopic dermatitis, with prevalence continuing to increase, underscoring the need for effective long-term treatment options.
Clinical Perspective
The positive topline Phase III results provide evidence that soficitinib achieved its primary efficacy objective while maintaining a safety profile consistent with previous clinical experience. However, because only topline findings have been released, the magnitude of treatment benefit and detailed safety outcomes cannot yet be independently evaluated.
The upcoming presentation of full efficacy and safety data at scientific congresses and publication in peer-reviewed journals will provide greater insight into the clinical profile of soficitinib and its potential role in the treatment of moderate-to-severe atopic dermatitis.
What This Means for Patients
The Phase III topline results suggest that soficitinib has the potential to become a new oral treatment option for patients with moderate-to-severe atopic dermatitis if it receives regulatory approval. The study met its primary endpoint and multiple secondary endpoints while demonstrating a safety profile consistent with earlier clinical studies and no new safety signals.
As detailed study results become available, clinicians and regulators will be better positioned to assess the therapy’s efficacy, safety, and potential place in the evolving treatment landscape for atopic dermatitis.
Reference
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.